Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Brian Laight"'
Autor:
Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath Singaravelu, Marian Hussein, Florian Gossart, Victoria A. Jennings, Lawton J. Stubbert, Madison Foster, Christopher Storbeck, Antonio Postigo, Elena Scut, Brian Laight, Michael Way, Philippe Erbs, Fabrice Le Boeuf, John C. Bell
Publikováno v:
Molecular Therapy: Oncolytics, Vol 14, Iss , Pp 246-252 (2019)
Vaccinia virus (VACV) possesses a great safety record as a smallpox vaccine and has been intensively used as an oncolytic virus against various types of cancer over the past decade. Different strategies were developed to make VACV safe and selective
Externí odkaz:
https://doaj.org/article/5d24d17ce15143d1abecc60ad4722916
Autor:
Noor Shakfa, Deyang Li, Gwenaëlle Conseil, Elizabeth Lightbody, Juliette Wilson-Sanchez, Ali Hamade, Stephen Chenard, Brian Laight, Afrakoma Afriyie-Asante, Kathrin Tyryshkin, Martin Köbel, Madhuri Koti
BackgroundHigh grade serous ovarian carcinoma (HGSC) is the most lethal gynecologic malignancy characterized by chemoresistance and high rates of recurrence. HGSC tumors display a high prevalence of tumor suppressor gene loss. Loss of BRCA1 and PTEN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cd404322f45b591f1f7cfbee0f08829
https://doi.org/10.1101/2022.06.27.497846
https://doi.org/10.1101/2022.06.27.497846
Autor:
Elena Scut, Madison Foster, Philippe Erbs, Adrian Pelin, Johann Foloppe, Victoria A. Jennings, Marian Hussein, Lawton J. Stubbert, Brian Laight, Antonio Postigo, Michael Way, Fabrice Le Boeuf, Florian Gossart, Julia Petryk, Christopher J Storbeck, Ragunath Singaravelu, John C. Bell
Publikováno v:
Molecular Therapy: Oncolytics, Vol 14, Iss, Pp 246-252 (2019)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Vaccinia virus (VACV) possesses a great safety record as a smallpox vaccine and has been intensively used as an oncolytic virus against various types of cancer over the past decade. Different strategies were developed to make VACV safe and selective